AstraNova BioLabs was founded on the conviction that the most transformative medicines emerge when scientific excellence meets unwavering operational discipline. We partner with biotech companies, pharmaceutical organizations, and academic research groups to provide the specialized capabilities that accelerate the translation of biological insights into clinical opportunities.
Our integrated approach — combining deep molecular pharmacology expertise, advanced phenotypic screening platforms, and sophisticated data science — enables us to support our partners across the full spectrum of early drug discovery, from initial target validation through IND-enabling candidate characterization.
We will translate the question into assay design, controls, timeline, and a reporting approach your stakeholders can act on.
Every conclusion we report is built on reproducible, rigorously validated data. We never sacrifice accuracy for speed.
We listen deeply to your scientific context and program pressures — your urgency is our urgency.
We invest heavily in new platforms and capabilities so our partners always have access to the latest science.
Our scientific community is globally connected, bringing diverse perspectives to every complex problem.
We measure our success by the milestones your program achieves — not just the deliverables we produce.
We begin by deeply understanding your target biology, program stage, and key scientific questions — ensuring every assay is designed to advance your specific decisions.
We match your program with the optimal assay platform and scientific approach from our deep portfolio of biochemical, cellular, and in vivo capabilities.
Our scientists execute with precision and communicate proactively. Every dataset is accompanied by clear interpretation and actionable next steps for your program.
Bring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
